Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | PDE4A | P27815 | 2/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.30 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1314604 | 1.00 | PDE4D (0.32) | PDE4DNPC1RAB9APDE4APDE4B | |
| SCHEMBL1294459 | 0.92 | NPC1 (0.36) | PDE4DNPC1RAB9APDE4APDE4B | |
| SCHEMBL1294688 | 0.92 | NPC1 (0.36) | PDE4DNPC1RAB9APDE4APDE4B | |
| SCHEMBL12117222 | 0.92 | NPC1 (0.36) | PDE4DNPC1RAB9APDE4APDE4B | |
| SCHEMBL1294457 | 0.92 | NPC1 (0.36) | PDE4DNPC1RAB9APDE4APDE4B | |
| SCHEMBL1294687 | 0.92 | NPC1 (0.36) | PDE4DNPC1RAB9APDE4APDE4B | |
| SCHEMBL1315238 | 0.89 | KDM4E (0.30) | — | |
| SCHEMBL17948080 | 0.86 | NPC1 (0.33) | NPC1RAB9AL3MBTL1GPR119HRH3 | |
| SCHEMBL1316080 | 0.85 | NPC1 (0.38) | PDE4DNPC1RAB9APDE4APDE4B | |
| SCHEMBL12686973 | 0.84 | NPC1 (0.41) | NPC1RAB9AL3MBTL1GPR119HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110274648-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110274648-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PDE4D 2633/4885NPC1 65/4885RAB9A 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.